《生命科学》 2022, 34(3): 261-267

溶质转运体在消化系统肿瘤中的研究进展

林佳莉 , 李　洁 , 袁继行^*

海军军医大学基础医学院医学遗传学教研室，上海 200433

摘　要：

溶质转运体(solute carriers, SLCs) 超家族是生物丰度位列第二的人体膜转运蛋白，仅次于G 蛋白偶联受体。它不仅在生理条件下介导分子或离子转运进而调节细胞功能，在病理条件下，特别是在消化系统肿瘤中也发挥重要作用，因而具有作为药物和基因治疗靶标的潜力。该文旨在对SLCs 超家族在消化系统肿瘤中的研究进展作简要介绍，内容主要包括SLCs 超家族分子概述，在各型消化系统肿瘤中的表达、作用和机制研究，SLCs 超家族分子作为药物和基因治疗靶标的方案和SLCs 超家族研究工作未来发展方向。对溶质转运体的研究可以为新药开发提供理论指导，为人类的SLCs 蛋白缺陷相关疾病的诊断和治疗开辟新路径。

通讯作者：袁继行 , Email:jihangyuan@smmu.edu.cn

Research progress of solute carriers in digestive tumors

LIN Jia-Li , LI Jie , YUAN Ji-Hang^*

Department of Medical Genetics, College of Basic Medical Sciences, Naval Medical University, Shanghai 200433, China

Abstract:

Solute carriers (SLCs) superfamily is the second most abundant human membrane transport protein and only second to G-protein coupled receptor. Not only can they mediate molecular or ionic transport and regulate cellular function under the physiological conditions, but also they play a vital role in digestive tumors in pathological conditions. Consequently, they have potential as targets for drug and gene therapies. This paper aims to make a brief introduction to the research progress of SLCs in digestive tumors, including the sketch of SLCs, their expression, roles and mechanisms in digestive tumors, their potential as targets for drug and gene therapies and their prospect in the field of research. All of the content can provide the theoretical instruction for related studies of new drugs and offer plans of diagnosis and treatment against SLCs deficiency associated diseases.

Communication Author：YUAN Ji-Hang , Email:jihangyuan@smmu.edu.cn